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To estimate the value of whole brain radiotherapy (WBRT) in the treatment of primary 
CNS lymphoma (PCNSL), it is important to recall the goals of treatment when 
confronted with this disease: presumably, our common goals of PCNSL treatment 
include: to improve neurological deficits, to improve or maintain quality of life, to delay 
neurological progression, to prolong progression-free survival, to prolong overall 
survival, and eventually to achieve a cure.  
Very few of these goals are achieved with WBRT in the current landscape of 
improved systemic therapy options for PCNSL. Historically, it had been recognized 
that PCNSL is less sensitive to irradiation than lymphomas elsewhere in the 
organism and might therefore potentially require higher doses to achieve local 
control. Accordingly, Radiation Therapy Oncology Group (RTOG) study 8315 
explored whether treating the whole brain at 40 Gy and increasing the tumor dose to 
60 Gy would result in improved outcome. In fact, median overall survival was only 
11.6 months from the start of radiotherapy; 16 of 26 patients with post-treatment CT 
scans were considered to have a complete response, a finding commonly cited to 
demonstrate the efficacy of RT in that disease. Importantly, however, these 16 
patients represent a highly selected population because patients who progressed 
during radiotherapy were not included here.1 
With the introduction of high-dose methotrexate into the first-line treatment of 
PCNSL, the survival outcome was greatly improved, establishing initial chemotherapy 
containing high-dose methotrexate as a new standard of care, superiority of which, 
e.g., over RT alone, was never formally demonstrated in a randomized clinical trial. 
However, it became also soon apparent that the encouraging activity of combined 
modality treatment came at a high prize. There was a major risk of severe 
neurotoxicity in surviving patients with a dramatic increase of risk in the elderly.2 The 
association of the administration of WBRT and delayed neurotoxicity defined by 
cognitive decline and characteristic changes on neuroimaging has been confirmed 
repeatedly ever since.3,4 Accordingly, the increasing awareness that the 
administration of WBRT was probably incompatible with long-term survival with 
adequate quality of life resulted in numerous approaches to treat PCNSL with 
systemic chemotherapy or combined systemic and intraventricular chemotherapy 
alone.5-9 Yet, although retrospective analysis had failed to support a role for WBRT in 
prolonging overall survival many years ago,10 clinical practice did not respond and 
WBRT continued to be used at many sites throughout the world, even in the first-line 
setting. Thus, it was stated that the formal demonstration that WBRT could be 
omitted from the first-line treatment of PCNSL without compromising overall survival 
required a randomized clinical trial. This major endeavor was eventually agreed upon 
with the formation of the German PCNSL Study Group in the late nineties and took 
until 2009 to complete enrolment. Patients with histologically confirmed PCNSL were 
to receive initial high-dose methotrexate chemotherapy, as monotherapy until 2005 
and in combination with ifosfamide thereafter, as initial treatment. Patients who 
achieved a complete response were then treated with consolidating WBRT or 
observation alone, based on a randomization done prior to induction chemotherapy. 
Patients without a complete response were to be treated per initial randomization 
with WBRT or high-dose cytarabine. The latter was considered the best alternative 
systemic treatment at the time the trial was designed. The initial report of the primary 
outcome measures11 as well as the final report12 indicate that the omission of WBRT 
from the initial treatment does not compromise survival whichever way the data are 
explored, including various subgroup analyses. 
Given the current dichotomy of PCNSL treatment of aiming for cure in young (fit) 
patients as opposed to maintaining remission in old (frail) patients,13 it becomes 
apparent that there is indeed no more role for WBRT in the initial treatment of the 
disease. If we want to cure young patients we cannot take the risk of inducing 
cognitive impairment for their remaining lifetime. In the elderly where we aim for 
maintaining the remissions we achieve, we should not use WBRT because of the 
strongly increased sensitivity of elderly patients to treatment-associated neurotoxicity. 
In light of the absence of a survival benefit for standard dose radiotherapy (30 x 1,5 
Gy) in the G-PCNSL-SG-1 trial,11,12 the rationale of using a lower dose of WBRT, e.g. 
13 x 1.8 Gy,14 in this setting remains doubtful. 
This leaves us with the consideration of whether PCNSL should be treated with 
WBRT at recurrence. A retrospective study of 48 patients treated with salvage WBRT 
reported a complete response rate of 58% and a partial response rate of 21%, and 
median survival from initiation of WBRT was 16 months.15 While these data may be 
cited to support the role of WBRT in recurrent PCNSL, randomized data are again 
more compelling and are in fact available looking into the G-PCNSL-SG1 trial. 
Activity of WBRT as a salvage treatment was demonstrated for progression-free 
survival, but even here not for overall survival,11 and the quality of post-progression 
survival with versus without WBRT remains to be explored. 
Overall, these data available in the public domain allow to formulate some 
hypotheses on the treatment of PCNSL as summarized in the Table, and I would be 
hesitant to randomize either young or fit patients, or elderly or unfit patients, for a trial 
containing WBRT at any dose. 
Is there no role for RT in this disease at all? Only prospective trials can support the 
claim that WBRT with hippocampal sparing is safer than standard WBRT, and this 
would only address the safety concern, not the efficacy concern. Could there be a 
role for focused RT e.g. in partial responders or to consolidate remission? Traditional 
views say “no”, but traditional views also said that there was no role for surgery until it 
was looked at in a reasonably sized patient population for the first time.16 
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Table. Key conclusions 
 There is no safe dose of WBRT for the brain 
 Reduced dose WBRT will not be more effective than standard dose WBRT 
 Intensifying chemotherapy up-front will not make WBRT for consolidation more 
effective 
 Intensifying chemotherapy up-front will not make WBRT for consolidation safer 
 PCNSL needs to be „cured“ up-front, not at recurrence: WBRT at recurrence 
remains an option, but probably does not prolong survival 
 
